Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoonyeong Lee

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 21, 2011
Bioactive lipids from the sponge Spirastrella abataKyoung Hwa Jang, Yoonyeong Lee, Chung J Sim, et al.
Marine Drugs|November 3, 2012
Cyclic Bis-1,3-dialkylpyridiniums from the sponge Haliclona spYoonyeong Lee, Kyoung Hwa Jang, Ju-Eun Jeon, et al.
Vaccines|April 27, 2026
Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6-35 Months: Results from a Multinational Phase 3 Randomised Controlled TrialYoonsun Yoon, Hye-Kyung Cho, Ki Hwan Kim, et al.
NPJ Vaccines|January 28, 2022
Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first doseMaria Rosario Capeding, Birkneh Tilahun Tadesse, Arijit Sil, et al.
The Lancet Regional Health. Western Pacific|June 6, 2022
A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of AgeJosefina Cadorna Carlos, Birkneh Tilahun Tadesse, Charissa Borja-Tabora, et al.
Vaccine|September 5, 2022
Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infantsTarun Saluja, Ganesh Kumar Rai, Shipra Chaudhary, et al.
The Lancet. Infectious Diseases|December 23, 2021
Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trialGanesh Kumar Rai, Tarun Saluja, Shipra Chaudhary, et al.
Eclinicalmedicine|November 5, 2020
Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind StudyMaria Rosario Capeding, Arijit Sil, Birkneh Tilahun Tadesse, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 10, 2025
Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, nonrandomized extension of a phase 1/2 trialJoon Young Song, Won Suk Choi, Jung Yeon Heo, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry Letters|December 21, 2011
Bioactive lipids from the sponge Spirastrella abataKyoung Hwa Jang, Yoonyeong Lee, Chung J Sim, et al.
Marine Drugs|November 3, 2012
Cyclic Bis-1,3-dialkylpyridiniums from the sponge Haliclona spYoonyeong Lee, Kyoung Hwa Jang, Ju-Eun Jeon, et al.
Vaccines|April 27, 2026
Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6-35 Months: Results from a Multinational Phase 3 Randomised Controlled TrialYoonsun Yoon, Hye-Kyung Cho, Ki Hwan Kim, et al.
NPJ Vaccines|January 28, 2022
Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first doseMaria Rosario Capeding, Birkneh Tilahun Tadesse, Arijit Sil, et al.
The Lancet Regional Health. Western Pacific|June 6, 2022
A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of AgeJosefina Cadorna Carlos, Birkneh Tilahun Tadesse, Charissa Borja-Tabora, et al.
Vaccine|September 5, 2022
Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infantsTarun Saluja, Ganesh Kumar Rai, Shipra Chaudhary, et al.
The Lancet. Infectious Diseases|December 23, 2021
Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trialGanesh Kumar Rai, Tarun Saluja, Shipra Chaudhary, et al.
Eclinicalmedicine|November 5, 2020
Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind StudyMaria Rosario Capeding, Arijit Sil, Birkneh Tilahun Tadesse, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 10, 2025
Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, nonrandomized extension of a phase 1/2 trialJoon Young Song, Won Suk Choi, Jung Yeon Heo, et al.
Pageof 1